Reported Earnings • May 14
First quarter 2026 earnings released: NT$0.046 loss per share (vs NT$0.32 loss in 1Q 2025) First quarter 2026 results: NT$0.046 loss per share (improved from NT$0.32 loss in 1Q 2025). Revenue: NT$60.5m (down 13% from 1Q 2025). Net loss: NT$1.82m (loss narrowed 85% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 14
Full year 2025 earnings released: NT$1.23 loss per share (vs NT$1.23 loss in FY 2024) Full year 2025 results: NT$1.23 loss per share (improved from NT$1.23 loss in FY 2024). Revenue: NT$61.5m (flat on FY 2024). Net loss: NT$48.1m (flat on FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Annuncio • Mar 05
NeoCore Technology Co., Ltd., Annual General Meeting, Jun 24, 2026 NeoCore Technology Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: no,9, lu k`o 1st rd., lujhu district, kaohsiung city Taiwan Reported Earnings • Nov 15
Third quarter 2025 earnings released: NT$0.42 loss per share (vs NT$0.36 loss in 3Q 2024) Third quarter 2025 results: NT$0.42 loss per share (further deteriorated from NT$0.36 loss in 3Q 2024). Revenue: NT$55.2m (up 235% from 3Q 2024). Net loss: NT$16.7m (loss widened 19% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
Second quarter 2025 earnings released: EPS: NT$0.31 (vs NT$0.39 loss in 2Q 2024) Second quarter 2025 results: EPS: NT$0.31 (up from NT$0.39 loss in 2Q 2024). Revenue: NT$53.7m (up 204% from 2Q 2024). Net income: NT$12.0m (up NT$27.1m from 2Q 2024). Profit margin: 22% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 14
First quarter 2025 earnings released: NT$0.31 loss per share (vs NT$0.40 loss in 1Q 2024) First quarter 2025 results: NT$0.31 loss per share (improved from NT$0.40 loss in 1Q 2024). Revenue: NT$69.6m (up 341% from 1Q 2024). Net loss: NT$12.3m (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Reported Earnings • Mar 19
Full year 2024 earnings released: NT$1.23 loss per share (vs NT$1.87 loss in FY 2023) Full year 2024 results: NT$1.23 loss per share (improved from NT$1.87 loss in FY 2023). Revenue: NT$61.5m (down 4.9% from FY 2023). Net loss: NT$48.1m (loss narrowed 26% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings. New Risk • Mar 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 34% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$68m revenue, or US$2.1m). Market cap is less than US$100m (NT$1.56b market cap, or US$47.5m). Annuncio • Mar 07
NeoCore Technology Co., Ltd., Annual General Meeting, Jun 26, 2025 NeoCore Technology Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,31, k`o chung, jhunan township, miaoli county Taiwan New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (NT$68m revenue, or US$2.1m). Market cap is less than US$100m (NT$1.30b market cap, or US$40.1m). Reported Earnings • Nov 18
Third quarter 2024 earnings released: NT$0.36 loss per share (vs NT$0.50 loss in 3Q 2023) Third quarter 2024 results: NT$0.36 loss per share (improved from NT$0.50 loss in 3Q 2023). Revenue: NT$16.5m (up 18% from 3Q 2023). Net loss: NT$14.0m (loss narrowed 28% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Reported Earnings • Aug 17
Second quarter 2024 earnings released: NT$0.39 loss per share (vs NT$0.39 loss in 2Q 2023) Second quarter 2024 results: NT$0.39 loss per share (in line with 2Q 2023). Revenue: NT$17.7m (up 40% from 2Q 2023). Net loss: NT$15.1m (flat on 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 30% per year, which means it is well ahead of earnings. New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (NT$61m revenue, or US$1.9m). Market cap is less than US$100m (NT$1.33b market cap, or US$40.8m). Reported Earnings • May 20
First quarter 2024 earnings released: NT$0.40 loss per share (vs NT$0.45 loss in 1Q 2023) First quarter 2024 results: NT$0.40 loss per share. Revenue: NT$15.8m (down 20% from 1Q 2023). Net loss: NT$15.6m (loss widened 63% from 1Q 2023). Annuncio • Apr 11
NeoCore Technology Co., Ltd., Annual General Meeting, Jun 25, 2024 NeoCore Technology Co., Ltd., Annual General Meeting, Jun 25, 2024. Reported Earnings • Mar 20
Full year 2023 earnings released: NT$1.87 loss per share (vs NT$1.49 loss in FY 2022) Full year 2023 results: NT$1.87 loss per share (further deteriorated from NT$1.49 loss in FY 2022). Revenue: NT$64.7m (down 27% from FY 2022). Net loss: NT$64.6m (loss widened 129% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (NT$74m revenue, or US$2.3m). Market cap is less than US$100m (NT$895.1m market cap, or US$28.4m). Reported Earnings • Aug 11
Second quarter 2023 earnings released: NT$0.39 loss per share (vs NT$0.52 loss in 2Q 2022) Second quarter 2023 results: NT$0.39 loss per share. Revenue: NT$12.7m (up 10.0% from 2Q 2022). Net loss: NT$15.2m (loss widened 53% from 2Q 2022). Reported Earnings • Mar 31
Full year 2022 earnings released: NT$1.49 loss per share (vs NT$0.91 loss in FY 2021) Full year 2022 results: NT$1.49 loss per share (further deteriorated from NT$0.91 loss in FY 2021). Revenue: NT$89.0m (flat on FY 2021). Net loss: NT$28.2m (loss widened 64% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Reported Earnings • Nov 19
Third quarter 2022 earnings released: NT$0.44 loss per share (vs NT$0.23 loss in 3Q 2021) Third quarter 2022 results: NT$0.44 loss per share (further deteriorated from NT$0.23 loss in 3Q 2021). Revenue: NT$21.1m (up 14% from 3Q 2021). Net loss: NT$8.28m (loss widened 86% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Reported Earnings • Aug 18
Second quarter 2022 earnings released: NT$0.52 loss per share (vs NT$0.19 loss in 2Q 2021) Second quarter 2022 results: NT$0.52 loss per share (down from NT$0.19 loss in 2Q 2021). Revenue: NT$11.5m (down 40% from 2Q 2021). Net loss: NT$9.94m (loss widened 171% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Reported Earnings • May 11
First quarter 2022 earnings released: NT$0.21 loss per share (vs NT$0.13 loss in 1Q 2021) First quarter 2022 results: NT$0.21 loss per share (down from NT$0.13 loss in 1Q 2021). Revenue: NT$28.8m (up 15% from 1Q 2021). Net loss: NT$3.94m (loss widened 56% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 3% per year. Reported Earnings • Nov 13
Third quarter 2021 earnings released: NT$0.09 loss per share (vs NT$0.097 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: NT$18.4m (down 29% from 3Q 2020). Net loss: NT$4.44m (loss narrowed 5.6% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 09
Second quarter 2021 earnings released: NT$0.08 loss per share (vs NT$0.12 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: NT$19.3m (down 15% from 2Q 2020). Net loss: NT$3.66m (loss narrowed 36% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2021 earnings released: NT$0.05 loss per share (vs NT$0.20 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$25.0m (up 18% from 1Q 2020). Net loss: NT$2.53m (loss narrowed 74% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 19
Full year 2020 earnings released: NT$0.56 loss per share (vs NT$0.25 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$93.3m (down 11% from FY 2019). Net loss: NT$27.1m (loss widened 128% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Annuncio • Mar 09
DR.Chip Biotechnology Incorporation, Annual General Meeting, Jun 15, 2021 DR.Chip Biotechnology Incorporation, Annual General Meeting, Jun 15, 2021. Is New 90 Day High Low • Mar 05
New 90-day high: NT$7.65 The company is up 4.0% from its price of NT$7.34 on 04 December 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 25
New 90-day low: NT$5.15 The company is down 34% from its price of NT$7.80 on 28 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Jan 06
New 90-day low: NT$6.13 The company is down 35% from its price of NT$9.45 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: NT$7.00 The company is down 35% from its price of NT$10.75 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day low: NT$7.27 The company is down 29% from its price of NT$10.20 on 19 August 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Reported Earnings • Nov 10
Third quarter 2020 earnings released: NT$0.09 loss per share The company reported a poor third quarter result with weaker earnings and control over expenses, although revenues were flat. Third quarter 2020 results: Revenue: NT$25.9m (flat on 3Q 2019). Net loss: NT$4.70m (down 280% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 28
New 90-day low: NT$7.80 The company is down 22% from its price of NT$10.00 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Sep 30
New 90-day low: NT$7.87 The company is down 16% from its price of NT$9.41 on 02 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.